1. Elimination of HPV-associated oropharyngeal cancers in Nordic countries
- Author
-
Antti Mäkitie, K. Miriam Elfström, Tuomas Lehtinen, Matti Lehtinen, Joakim Dillner, Michael Pawlita, Simopekka Vänskä, Tim Waterboer, Mari Nygård, HUS Head and Neck Center, Clinicum, and Korva-, nenä- ja kurkkutautien klinikka
- Subjects
Adult ,Male ,Human papillomavirus ,Adolescent ,Epidemiology ,VACCINE ,Scandinavian and Nordic Countries ,HUMAN-PAPILLOMAVIRUS ANTIBODIES ,01 natural sciences ,DISEASE ,Cancer screening ,03 medical and health sciences ,0302 clinical medicine ,INFECTION ,Medicine ,Humans ,030212 general & internal medicine ,0101 mathematics ,Young adult ,Finland ,Aged ,E6 ,Sweden ,RISK ,Oropharyngeal cancer ,business.industry ,Norway ,Incidence (epidemiology) ,010102 general mathematics ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,virus diseases ,Hpv vaccination ,Middle Aged ,3142 Public health care science, environmental and occupational health ,3. Good health ,PREVALENCE ,Oropharyngeal Neoplasms ,Early adolescents ,Female ,business ,Birth cohort ,Oropharyngeal Cancers ,Demography - Abstract
Incidence of human papillomavirus (HPV, most notably HPV type 16) associated oropharyngeal squamous cell carcinoma (OPSCC) among middle-aged (50?69 year-old) males has tripled in four high income Nordic countries (Denmark, Finland, Norway and Sweden) over the last 30 years. In Finland and Sweden, this increase was preceded by an HPV16 epidemic in fertile-aged populations in the 1980?s. The recent implementation of school based prophylactic HPV vaccination in early adolescent boys and girls will gradually decrease the incidence, and eventually eliminate the HPV-associated OPSCCs (especially tonsillar and base of tongue carcinomas) in the Nordic countries. However, beyond the adolescent and young adult birth cohorts vaccinated, there are approximately 50 birth cohorts (born in 1995 or before) that would benefit from screening for HPV-associated OPSCC. This article reviews the need, prerequisites, proof-of-concept trial and prospects of preventing HPVassociated OPSCC in the Nordic countries.
- Published
- 2021